List of Excipients in Branded Drug NORETHINDRONE ACETATE

« Back to Dashboard

Generic Drugs Containing NORETHINDRONE ACETATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	norethindrone acetate	0378-7291	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	norethindrone acetate	0378-7291	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	norethindrone acetate	0378-7291	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in NORETHINDRONE ACETATE?

# Of NDCs	Excipient
3	ANHYDROUS LACTOSE
9	CELLULOSE, MICROCRYSTALLINE
2	LACTOSE

Norethindrone Acetate Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Norethindrone acetate is an established small-molecule progestin with a mature generic market. The strongest commercial opportunities are not composition-of-matter patents. They are low-cost tablets, improved dose uniformity, differentiated release profiles, combination products, and patient-specific delivery formats. Excipient selection should prioritize chemical stability, content uniformity at low dose, rapid and reproducible dissolution, manufacturability, and regulatory simplicity.

What is the commercial market for norethindrone acetate?

Norethindrone acetate is an orally active progestin used in products for abnormal uterine bleeding, endometriosis, amenorrhea, and hormone therapy. It is also used in combination with ethinyl estradiol in oral contraceptive products, although contraceptive combinations commonly use norethindrone rather than norethindrone acetate as the progestin component.

The principal reference product for single-ingredient norethindrone acetate tablets is Aygestin, historically marketed in 5 mg strength. Generic products are available through the abbreviated new drug application pathway.

Product category	Typical strength or format	Primary use	Commercial position
Norethindrone acetate tablet	5 mg	Abnormal uterine bleeding, endometriosis, amenorrhea	Mature generic opportunity
Norethindrone acetate tablet	10 mg or higher dose through regimen titration	Selected gynecologic indications	Smaller volume, higher dose-flexibility value
Norethindrone acetate plus estrogen	Product-specific	Menopausal hormone therapy	Combination-product opportunity
Norethindrone or norethindrone acetate contraceptive combination	Product-specific	Contraception	Established, competitive segment
New oral formulation	1 to 5 mg target range	Improved tolerability or adherence	Differentiated product opportunity
Long-acting or local delivery system	Product-specific	Endometriosis or gynecologic indications	Higher development and regulatory risk

Norethindrone acetate is a small molecule, not a biologic. Biosimilar competition is therefore not relevant. Competition comes from generic tablets, branded hormone products, combination products, and alternative progestins.

What excipients are appropriate for norethindrone acetate tablets?

The most practical platform is an immediate-release compressed tablet using a conventional direct-compression or wet-granulation formulation. Norethindrone acetate has a relatively low active load in a 5 mg tablet, so excipient selection must support content uniformity across the batch.

Recommended excipient functions

Formulation function	Suitable excipient classes	Strategic rationale
Dilution and tablet mass	Lactose, microcrystalline cellulose, dibasic calcium phosphate, mannitol	Provides uniform blend volume and acceptable tablet weight
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule strength and tablet mechanical integrity
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force; over-lubrication must be controlled
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide or permitted colorants	Improves handling, identification, swallowability, and light protection
Moisture-control excipient	Low-moisture fillers and barrier coating systems	Reduces hydrolysis or degradation risk where supported by stability data

A lactose-based formulation is commercially familiar and cost-efficient. Microcrystalline cellulose is useful where stronger compaction, lower friability, or better disintegration control is required. Mannitol can support a premium orally disintegrating tablet, although it raises cost and may require taste-masking work.

How should excipient strategy address low-dose content uniformity?

Content uniformity is the central technical issue for a 5 mg norethindrone acetate tablet. Poor distribution of the active ingredient can arise from segregation, differences in particle size, electrostatic charging, or insufficient blending.

A robust development strategy should include:

1. Particle-size control for the active ingredient.
2. Deagglomeration or sieving before blending.
3. Ordered mixing with a carrier excipient where needed.
4. Granulation if direct compression produces unacceptable segregation.
5. Blend-uniformity testing at multiple blender locations.
6. In-process tablet weight and assay controls.
7. Dissolution testing using a discriminatory method.

Direct compression offers lower processing cost and fewer unit operations. Wet granulation can improve blend uniformity and reduce segregation but adds water, drying, equipment, and process-validation requirements. For a mature generic product, direct compression is usually the first economic option. Granulation becomes more attractive when the active has poor flow, low bulk density, electrostatic behavior, or a wide particle-size distribution.

What dissolution and bioavailability issues affect formulation design?

Norethindrone acetate is a lipophilic steroidal compound. Dissolution performance can become a limiting factor if the formulation uses excessive lubricant, produces a dense compact, or contains poorly wetting active particles.

Excipient screening should evaluate:

• Disintegration time.
• Dissolution across physiologically relevant pH conditions.
• Effect of surfactant concentration.
• Tablet hardness and compression force.
• Magnesium stearate level and blending time.
• Active-particle size and surface area.
• Stability after exposure to humidity and elevated temperature.

A superdisintegrant combination may improve robustness, but excessive disintegrant can weaken tablets or alter handling characteristics. Sodium lauryl sulfate or another wetting agent may improve dissolution, but it can create tolerability, taste, and regulatory-justification issues. The preferred approach is to first optimize particle engineering, compression, and disintegration before adding a surfactant.

What formulation patents could protect norethindrone acetate products?

The active ingredient itself is commercially mature, so new intellectual-property value would generally come from formulation, delivery, manufacturing, or clinical-use claims.

Formulation patent opportunities

Potential claim themes include:

• A specific excipient ratio that improves dissolution or stability.
• A low-dose tablet with defined content-uniformity parameters.
• A modified-release matrix for sustained progestin exposure.
• A bilayer tablet separating norethindrone acetate from an estrogen.
• A moisture-protective coating system.
• An orally disintegrating tablet with taste masking.
• A multiparticulate capsule or tablet.
• A fixed-dose combination with estrogen or another gynecologic active.
• A formulation with reduced food effect or reduced pharmacokinetic variability.

Patentability depends on novelty, non-obviousness, enablement, and credible technical benefit. Broad claims covering ordinary fillers, binders, lubricants, and disintegrants are vulnerable when the formulation is predictable from standard pharmaceutical practice. Stronger positions require comparative data showing an unexpected result, such as improved dissolution under discriminatory conditions, enhanced stability, reduced variability, or a meaningful manufacturing advantage.

Manufacturing patent opportunities

Manufacturing claims may cover:

• Particle-size-controlled norethindrone acetate.
• A specific micronization or crystallization process.
• A dry-granulation process with defined roller-compaction parameters.
• A blend-order or premix procedure that improves content uniformity.
• A continuous manufacturing process.
• A coating process that reduces moisture ingress.
• A packaging system that protects the drug from light or humidity.

Manufacturing patents can create a barrier even when competitors can legally sell the same active ingredient. Their commercial value depends on whether the process is necessary for acceptable product performance or can be designed around without material cost or quality loss.

What is the Orange Book status of norethindrone acetate?

Norethindrone acetate products are generally regulated as small-molecule prescription drugs. FDA-approved products may be listed in the Orange Book by applicant, dosage form, strength, therapeutic equivalence rating, and patent or exclusivity information where applicable.

The relevant regulatory pathway for a conventional generic tablet is an ANDA. A generic applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, together with conformity to quality and manufacturing requirements.

For a mature norethindrone acetate tablet:

• New chemical entity exclusivity is not expected.
• Orphan-drug exclusivity is not inherent to the product.
• Biosimilar substitution rules do not apply.
• Any remaining product-specific exclusivity or listed patent must be assessed against the current Orange Book entry.
• Formulation or method-of-use patents may affect commercial launch if they are listed or otherwise enforceable.

The Orange Book does not capture every potentially relevant patent. It primarily identifies patents and regulatory exclusivities submitted for approved products under applicable FDA rules. Unlisted formulation, manufacturing, or contractual rights may still affect litigation or licensing strategy.

When does norethindrone acetate lose exclusivity?

The active ingredient has been marketed for decades, so the original compound exclusivity has expired. Commercial exclusivity for a new norethindrone acetate product would depend on the specific product, formulation, indication, and approval date.

The practical exclusivity framework is:

Exclusivity type	Relevance to norethindrone acetate
New chemical entity exclusivity	Generally unavailable for this established active
Five-year new-drug exclusivity	Relevant only to a qualifying new product, not the old active itself
Three-year clinical-investigation exclusivity	Possible for a new indication or formulation supported by required clinical work
Orphan exclusivity	Possible only for a qualifying orphan indication
Pediatric exclusivity	Product-specific and dependent on FDA requirements
Patent protection	Most plausible route for a differentiated new formulation
Regulatory exclusivity for a generic	Generally limited compared with innovative products

A generic launch strategy should therefore focus on patent certification, Paragraph IV risk, manufacturing readiness, and commercial access rather than relying on residual molecule exclusivity.

Which companies are challenging norethindrone acetate products?

Generic competition in norethindrone acetate is typically fragmented among ANDA sponsors, contract manufacturers, and specialty pharmaceutical companies. The commercial landscape can change as applicants enter or exit the market, products are discontinued, and supply contracts move between manufacturers.

A reliable competitive review should compare:

• Approved ANDA holders.
• Current marketed products rather than historical approvals.
• Strengths and dosage forms.
• Therapeutic-equivalence ratings.
• Drug shortage or discontinuation history.
• Wholesale acquisition cost and payer reimbursement.
• Manufacturing location and supply redundancy.
• Any Paragraph IV certifications or patent litigation.

Because this market is mature, the largest competitive advantage may come from dependable supply, low minimum order quantities, and payer coverage rather than clinical differentiation.

What Paragraph IV and litigation risks exist?

Paragraph IV litigation is most relevant when a generic applicant challenges an Orange Book-listed patent covering an innovative formulation, method of use, or combination product. For a standard immediate-release norethindrone acetate tablet based on an old reference product, the principal risk is usually limited to any currently listed product-specific patent.

A sponsor pursuing a differentiated product should conduct:

• Orange Book patent review.
• Patent-family analysis in the United States and key foreign markets.
• Freedom-to-operate analysis for formulation and manufacturing claims.
• Review of prior ANDA litigation and settlement terms.
• Assessment of skinny-label or section viii strategies where appropriate.
• Evaluation of labeling overlap with protected methods of use.

Settlement agreements can delay generic entry, limit launch rights, or provide authorized-generic arrangements. Their commercial effect depends on the settlement date, patent expiry, permitted launch date, and whether the agreement includes supply or licensing provisions.

What are the strongest commercial opportunities?

Low-cost generic tablet

This is the lowest-risk opportunity. A conventional 5 mg tablet can compete through cost, reliable supply, packaging efficiency, and broad pharmacy distribution. The main limitation is commodity pricing and limited room for premium margins.

Premium adherence formulation

An orally disintegrating tablet, smaller tablet, or easier-to-swallow film-coated product could target patients with swallowing difficulty or poor adherence. The product would require taste masking, rapid disintegration, moisture protection, and a clear clinical or patient-use rationale.

Modified-release product

A sustained-release formulation could reduce dosing frequency or improve tolerability. Development risk is higher because pharmacokinetic performance, dose dumping, food effects, and clinical bridging may become important. The opportunity is more defensible if the product addresses a defined treatment problem rather than merely changing release rate.

Fixed-dose combination

Combining norethindrone acetate with an estrogen or another gynecologic active can create a product-specific patent position. Risks include combination stability, dose optimization, labeling complexity, and competition from established hormone-therapy products.

Specialty gynecology supply

A manufacturer can target hospitals, specialty pharmacies, and women’s-health distributors with reliable supply, flexible pack sizes, and patient-support services. This model may generate better economics than undifferentiated retail generic competition.

How does norethindrone acetate compare with competing progestins?

Attribute	Norethindrone acetate	Medroxyprogesterone acetate	Micronized progesterone	Drospirenone
Product maturity	High	High	High	High
Generic competition	Broad	Broad	Broad	Broad but product-specific
Oral tablet platform	Established	Established	Established	Established
Main formulation challenge	Low-dose uniformity and dissolution	Dose and release flexibility	Poor water solubility and capsule performance	Stability and combination design
Differentiation potential	Moderate	Moderate	Moderate to high	Moderate
Biosimilar risk	None	None	None	None
Likely commercial advantage	Cost, supply, adherence	Indication breadth and dose range	Delivery and tolerability	Combination positioning

Norethindrone acetate is most attractive where a sponsor can combine an established active with a formulation or distribution advantage. It is less attractive as an undifferentiated tablet without cost or supply advantages.

What geographic markets offer the best opportunity?

The United States offers a regulated generic market with established ANDA pathways and Orange Book visibility. Europe and other regulated markets provide opportunities through national or decentralized procedures, but reference-product requirements, naming, reimbursement, and substitution rules differ.

Emerging markets may offer higher volume potential but introduce risks involving:

• Local registration requirements.
• Price controls.
• Tender concentration.
• Counterfeit exposure.
• Local manufacturing rules.
• Currency volatility.
• Variable enforcement of formulation patents.

A global strategy should use a common core formulation where possible, while adapting excipient permissions, labeling, packaging, and stability protocols to local requirements.

Key Takeaways

• Norethindrone acetate is a mature small-molecule progestin with no biosimilar risk.
• The strongest near-term opportunity is a cost-efficient, high-uniformity immediate-release tablet.
• Excipient selection should focus on blend uniformity, dissolution, tablet robustness, and stability.
• Microcrystalline cellulose, lactose, crospovidone, croscarmellose sodium, colloidal silicon dioxide, and controlled lubricant levels are practical development starting points.
• Patent value is more likely to arise from formulation, manufacturing, combination, or delivery claims than from the active ingredient.
• Orally disintegrating, modified-release, fixed-dose combination, and specialty-distribution products offer higher margins but carry greater development risk.
• Orange Book and Paragraph IV analysis must be product-specific and current because listed patents and marketed generic participants change over time.
• Manufacturing reliability and payer access may be more important than technical differentiation in the commodity tablet segment.

FAQs

Can norethindrone acetate be formulated as an orally disintegrating tablet?

Yes. The principal challenges are taste masking, rapid disintegration, tablet friability, moisture sensitivity, and maintaining assay uniformity at a low active load. Mannitol, crospovidone, flavor systems, and moisture-barrier packaging may support the platform.

Is lactose suitable for norethindrone acetate tablets?

Lactose is a practical filler for conventional tablets when compatibility, moisture exposure, and patient-specific tolerability have been assessed. The final choice depends on stability, compression, dissolution, and regulatory requirements.

Does norethindrone acetate require a lipid-based formulation?

Not usually for a conventional immediate-release tablet. A lipid-based system may be considered if dissolution or exposure is inadequate, but it adds formulation complexity and may increase development and manufacturing cost.

Can a norethindrone acetate formulation receive new patent protection?

Yes, if the formulation or manufacturing process satisfies applicable patentability standards. The strongest candidates generally require defined composition limits and data showing an unexpected technical effect.

Is a generic norethindrone acetate tablet eligible for biosimilar substitution?

No. Norethindrone acetate is a small molecule. Generic substitution is governed by pharmaceutical-equivalence and therapeutic-equivalence rules, not the biosimilar framework.

References

1. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/ame/index.cfm

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information

4. DailyMed. (n.d.). Aygestin: Norethindrone acetate tablet labeling. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.